Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 4, 2007

LFB Biotechnologies Creates New Entity under MAbgène Brand

  • The LFB Group created a new company under the MAbgène brand name to be controlled by LFB biotechnologies. It will host the industrial and commercial activities currently performed at MAbgène's manufacturing site in Alès, France and all MAbgène staff.

    LFB Biotechnologies, a subsidiary of the LFB group, will acquire 41% of the stock capital and 51% of the voting rights in the new entity. LFB says that its long-term objective is to acquire all the shares in the newly formed company.

    LFB will provide MAbgène with funds to develop its activities, build new operating facilities, and recruit additional personnel.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »